H1 and Q2 2026 Results

Fixed-income investor update

27 July 2026

Cautionary statements regarding forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement:

This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the risk of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data and artificial intelligence in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet our sustainability targets, regulatory requirements or stakeholder expectations with respect to the environment; the risk of failure to meet regulatory and ethical expectations on commercial practices, including anti-bribery anti-corruption, anti-fraud and scientific exchanges; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property risks related to the Group's products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of geopolitical and/or macroeconomic volatility disrupting the operation of our global business; the risk of failure in internal control, financial reporting or the occurrence of fraud; and the risk of unexpected deterioration in the Group's financial position.

Disclaimer

This presentation is neither an offer to sell nor a solicitation of an offer to buy any securities and shall not constitute an offer, solicitation, or sale in any jurisdiction in which an offer, solicitation, or sale is unlawful.

Non-GAAP measures

This presentation contains financial measures that are not calculated in accordance with generally accepted accounting principles (“GAAP”). These non-GAAP financial measures include net debt as well as our core financial measures and constant exchange rate (CER) growth rates. Non-GAAP measures included in this presentation should be considered in addition to, but not as substitutes for, the information we prepare in accordance with GAAP and as a result should be reviewed in conjunction with our financial statements. We provide reconciliations on slide 33 and 34 in the Appendix to this presentation between our non-GAAP financial measures and the respective most directly comparable financial measure calculated and presented in accordance with GAAP. However, the Company presents Core EPS guidance only at CER. It is unable to provide guidance on a Reported/GAAP basis because the Company cannot reliably forecast material elements of the Reported/GAAP result, including the fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions.

Key messages

Strong growth delivery continues

Total revenue +6% in H1 2026

Continued pipeline momentum

Positive results from 6 Phase III programmes in H1 2026 – including 3 new molecular entities

Advancing towards $80bn 2030 Total Revenue ambition – and beyond

Significant pipeline progress increases confidence

Balanced and diversified company

By therapy area and geography

Focus on financial discipline – capital allocation priorities remain unchanged

FY 2026 guidance reiterated

All growth rates at CER

Commercial performance and pipeline delivery in H1 2026 drive confidence in $80bn Total Revenue ambition

SUSTAINED COMMERCIAL MOMENTUM

- **+6%** Total Revenue
- **+11%** Total Revenue, ex. *Farxiga* and *Brilinta*[1]
- **+11%** Core EPS

MEANINGFUL PROGRESS FOR OUR PIPELINE[2]

- **6** positive key Phase III programme readouts
- 1st Phase III data for 3 NMEs: sonesitatug vedotin; tozorakimab; efzimfotase alfa
- 1st approval for 2 NMEs: ETCAMAH™ camizestrant; BAXFENDY™ baxdrostat

All growth rates at CER compared to H1 2025. 1. Revenue growth calculated excluding *Farxiga* and *Brilinta* following LOEs in certain major markets. 2. Since FY 2025 results.
Appendix: Glossary.

Growth driven by diverse sources of business and global presence

H1 2026 | % Product Revenue by therapy area



H1 2026 | % Product Revenue by geography



Strength across therapy areas

H1 2026 | +6% Product Revenue ($m)[1]



Growth across geographies

H1 2026 | + 6% Product Revenue ($m)[1]



ID = Infectious Disease (previously Vaccines & Immune Therapies). Due to rounding, the sum of the percentages may not agree to totals. 1. All growth rates at CER compared to H1 2025.
Appendix: Glossary.

Continued pipeline momentum in H1 2026

KEY POSITIVE PHASE III PROGRAMME READOUTS

EMERALD-3
Imfinzi + Imjudo
liver cancer

VOLGA
Imfinzi ± Imjudo
bladder cancer

NME
CLARITY-Gastric01
sonesitatug vedotin
gastric cancer

NME
OBERON / TITANIA / MIRANDA
tozorakimab
COPD

NME
HICKORY / CHESTNUT / MULBERRY
efzimfotase alfa
hypophosphatasia

I CAN
Ultomiris
IgAN

FIRST MAJOR MARKET APPROVALS FOR NEW INDICATIONS

BREAST CANCER	***Enhertu*** DESTINY-Breast05	***Datroway*** TROPION-Breast02	**GU CANCERS**	***Imfinzi*** POTOMAC	**HYPER-TENSION**	***Baxfendy*** BaxHTN	NME
	Enhertu DESTINY-Breast11	***Etcamah*** SERENA-6 NME		***Truqap*** CAPItello-281	**ASTHMA**	***Breztri*** KALOS/LOGOS	

Collaboration partners: Daiichi Sankyo (*Datroway, Enhertu*)
Appendix: Glossary.

Oncology – H1 and Q2 2026

Total Revenue +15% in Q2 and H1 2026 driven by robust global demand across key medicines

Oncology

H1 2026 $14.1bn, +15%



Q2 2026: key dynamics

- ***Tagrisso*** +6%, extending 1L leadership with accelerating FLAURA2 uptake in growing combo market
- ***Imfinzi*** +27%, ***Imjudo*** (7%), robust global demand growth driven by new launches
- ***Calquence*** +16%, continued BTKi leadership in 1L CLL across major markets
- ***Enhertu*** +31%, strong global demand growth, driven by breast indications
- ***Truqap*** +37%, continued ex-US growth, 2L US share stable
- ***Datroway*** $55m, share in 2L *EGFR*m lung increasing, leading position in 3L+

Key regulatory approvals:

- US (*Datroway* TROPION-Breast02, *Enhertu* DESTINY-Breast05 & -11, *Imfinzi* POTOMAC, *Truqap* CAPItello-281)
- EU *(Enhertu* DESTINY-PanTumor02[2], *Etcamah* SERENA-6)
- JP (*Calquence* AMPLIFY, *Etcamah* SERENA-6, *Imfinzi* MATTERHORN)

All growth rates at CER compared to same financial period in 2025. 1. Others is inclusive of *Datroway*. 2. Approval based on results from DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02.
Collaboration partners: Daiichi Sankyo (*Enhertu*, *Datroway*), Merck & Co., Inc. (*Lynparza*), Hutchmed (*Orpathys*).
Appendix: Glossary.

Oncology – leadership in *EGFR*m lung cancer

Commercial, BD and pipeline strength consolidate our position across *EGFR*m NSCLC

Continued strong growth with *Tagrisso* globally

#1 3rd gen EGFR TKI prescribed globally[1]

>75% FLAURA2 share of 1L US combination market[2]

Zegfrovy broadens reach across *EGFR*m disease[3]

- **Already approved in 2L in US, launched in China**
- **1L filings submitted based on global Phase III WU-KONG28 trial[4]**

Pipeline ensures continued leadership

Establishing novel combinations in 2L+

TROPION-Lung15	***Datroway* ± *Tagrisso***	**H2 2026**
SAFFRON	***Tagrisso* + *Orpathys***	**H2 2026**

Expanding 1L disease leadership

TROPION-Lung14	***Datroway* + *Tagrisso***	**>2027**

1. IQVIA MIDAS monthly data by May 2026. 2. IQVIA US May 2026 ATU data. 3. *Zegfrovy* is approved in the US and China for the treatment of adult patients with locally advanced or metastatic NSCLC with *EGFR* exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. 4. A Supplemental New Drug Application for approval in the 1st-line setting has been submitted to the US FDA and China's CDE.
AstraZeneca has entered into an exclusive license agreement with Dizal Pharmaceutical Co., Ltd for *Zegfrovy* (sunvozertinib). AstraZeneca will acquire worldwide rights to develop and commercialise *Zegfrovy*. The transaction is expected to close in the second half of 2026, subject to customary closing conditions and regulatory clearances. Collaboration partners: Daiichi Sankyo (*Datroway*), Hutchmed (*Orpathys*).
Appendix: Glossary.

Oncology – Phase III data readouts transforming practice

Data readouts reinforce AstraZeneca potential in areas of high unmet need

VOLGA | *Imfinzi* + EV +/- *Imjudo* reframing outcomes with cisplatin-ineligible MIBC

***Imfinzi* + EV**	**Met primary endpoint:** Clinically meaningful improvements in EFS and OS
Imfinzi* + EV + *Imjudo	Clinically meaningful EFS improvement, OS trend

Imfinzi data across bladder cancer spectrum

High-risk NMIBC	MIBC	1L mUC
POTOMAC ✓	cis-eligible | NIAGARA ✓	NILE ✓
	cis-ineligible | VOLGA ✓	

CLARITY-Gastric01 | sone-ve transforming outcomes in 2L+ Claudin 18.2+ gastric cancer

Met primary endpoint: Highly clinically meaningful OS improvement in patients treated with ≥2 prior therapies[1]

Met key secondary endpoint: Highly clinically meaningful OS benefit in patients treated with ≥1 prior therapy

>180k	patients with 2L+ Claudin 18.2+ gastric cancer[2]
20%	patients alive 1 year after diagnosis with advanced gastric cancer

First global Phase III to show survival benefit with Claudin 18.2 ADC in 2L+ gastric cancer setting

1. For the other dual primary endpoint of PFS as assessed by blinded independent central review, results showed a trend toward improved PFS in patients treated in the 2nd and later-line setting but did not reach statistical significance.
2. Across US, EU5, Japan and China.

Appendix: Glossary.

BioPharmaceuticals – H1 and Q2 2026

Total Revenue -5% to $11.2bn; CVRM LoE impact largely offset by growth in R&I

R&I

H1 2026 $4.8bn, +9%



CVRM

H1 2026 $6.1bn, -12%



Q2 2026: key dynamics

- ***Fasenra*** +13%, sustained IL-5 leadership in asthma, EGPA growth, ongoing China launch
- ***Breztri*** +20%, fastest growing medicine in expanding FDC triple class in COPD
- ***Tezspire*** +45%, sustained demand growth in severe asthma supported by nasal polyps launch
- ***Saphnelo*** +24%, increasing penetration of i.v. formulation; subcutaneous launch in US and EU
- ***Farxiga*** (19%), generic competition in US and Japan; VBP in China; growth in other regions
- ***Wainua*** +58%, demand growth in ATTR-PN

Key regulatory approvals:

- US, EU, JP, CN (*Fasenra* NATRON)
- EU CHMP (*Breztri* KALOS / LOGOS)

All growth rates at CER compared to same financial period in 2025. Collaboration partners: Amgen (*Tezspire*), Ionis (*Wainua).*
Appendix: Glossary.

BioPharmaceuticals – key pipeline developments in Q2 2026

Wainua | CARDIO-TTRansform Phase III trial

- ATTR-CM trial in contemporary patient population
- Primary endpoint not met; *Wainua* monotherapy showed nominal statistically significant benefit
- Data to be presented at ESC congress in August

Additional catalysts | Advancing late-stage assets

SARA (AZD6234)
Phase III trial initiating

laroprovstat + rosuvastatin
Phase III trial initiating

Positive Phase III data for **tozorakimab** at ERS

elecoglipron | Phase IIb VISTA and SOLSTICE at ADA

Clinically meaningful efficacy
11.8% weight loss[1] and **1.9%** HbA1c reduction[2]

Favourable safety
GI tolerability and safety consistent with GLP-1 RA class

Convenient small molecule
No food or fluid restrictions; combinable oral small molecule

Initiating a broad Phase III programme:

EMBOLD	ELUMINATE	ELEVATE
- Obesity or overweight (± T2D) - elecoglipron monotherapy FSI	- T2D - elecoglipron ± dapagliflozin FSI	- Outcomes trials on background dapa + other SOC - HFpEF trial - CKD (± T2D) trial

1. Non-placebo adjusted at week 36. 2. Non-placebo adjusted at week 26.
Appendix: Glossary.

Rare Disease – H1 and Q2 2026

Total Revenue $4.9bn in H1 driven by continued patient demand across the portfolio

Rare Disease

H1 2026 $4.9bn, +11%



Q2 2026: key dynamics

C5 Franchise

- ***Ultomiris*** +12%, growth across indications, including within the competitive gMG and PNH markets
- ***Soliris*** (28%), successful conversion to *Ultomiris* and additional impact from biosimilars in US and EU

Beyond Complement

- ***Strensiq*** +36%, strong global demand from patients with HPP
- ***Koselugo*** +27%, continued growth, including newly launched adult indication

All growth rates at CER compared to same financial period in 2025. 1. *Ultomiris* Total Revenue includes sales of *Voydeya*. 2. Others includes *Kanuma* and *Beyonttra* (JP only).
Collaboration partners: Merck & Co., Inc. (*Koselugo*) concluded in August 2025, BridgeBio (*Beyonttra*).
Appendix: Glossary.

Rare Disease – Phase III presentations at congresses across rare disease indications

Ultomiris | Expanding further into nephrology with I CAN Phase III trial

43% reduction in proteinuria in IgAN patients[1]

Significant proteinuria reduction, seen as early as 10 weeks

Well positioned in an increasingly competitive IgAN market

Filed in US and JP

efzimfotase alfa | Transformative data for paediatric HPP with MULBERRY and CHESTNUT

Clinically meaningful improvement in bone health

Significant improvement in function and QoL measures

361 days per year free from ISRs[2,3]

Filing in major markets for broad HPP population

1. Barratt J, et al Ravulizumab in IgA nephropathy: a prespecified interim analysis of a randomized phase 3 trial (I CAN). Presented at European Renal Association (ERA) Congress; 2026 Jun 6; Glasgow, Scotland. 2. Simmons JH, et al Efficacy and Safety of Alkaline Phosphatase (ALP) Enzyme Replacement Therapy (ERT) Efzimfotase Alfa in Children with Hypophosphatasia (HPP): Results of MULBERRY and CHESTNUT as Part of a Three-trial Phase 3 Clinical Program. Presented at ICCBH congress; 2026 Jun 28, Montreal, Canada. 3. The median number of ISR-free days is based on estimates of annualised patient-level ISR days. ISR = injection site reaction
Appendix: Glossary.

Continuing pipeline momentum with key Phase III readouts

H1 2026

- **EMERALD-3** | *Imfinzi + Imjudo* locoregional HCC
- **VOLGA** | *Imfinzi ± Imjudo* muscle-invasive bladder cancer
- **OBERON/TITANIA/MIRANDA** | tozorakimab COPD
- **I CAN** | *Ultomiris* IgAN
- **ARTEMIS** | *Ultomiris* CSA-AKI
- **HICKORY/CHESTNUT/MULBERRY** | efzimfotase alfa hypophosphatasia

H2 2026

- **AVANZAR** | *Datroway + Imfinzi* 1L NSQ/NSQ TROP2+ NSCLC
- **TROPION-Lung15** | *Datroway ± Tagrisso* 2L *EGFR*m NSCLC
- **SERENA-4** | *Etcamah* 1L HR+ HER2- adv. breast cancer
- **PACIFIC-9** | *Imfinzi +* oleclumab/ monalizumab unresect. stg. III NSCLC
- **SAFFRON** | *Tagrisso + Orpathys* 2L *EGFR*m NSCLC
- **CLARITY-Gastric01** | sonesitatug vedotin 2L+ CLDN18.2+ gastric cancer
- **CARDIO-TTRansform** | *Wainua* ATTR-CM
- **CROSSING** | *Tezspire* eosinophilic esophagitis
- **TMA-313** | *Ultomiris* HSCT-TMA (adults)

H1 2027

- **TROPION-Lung07** | *Datroway* 1L NSQ/NSQ TROP2+ NSCLC
- **eVOLVE-Lung02** | volrustomig 1L mNSCLC
- **DAISY** | *Saphnelo* systemic sclerosis
- **IRIS** | *Saphnelo* lupus nephritis
- **LAVENDER** | *Saphnelo* cutaneous lupus erythematosus
- **BalanceD-HF** | balcinrenone + dapagliflozin HF with renal impairment
- **AZURE-LDL/AZURE-HeFH** | laroprovstat dyslipidemia
- **ZENITH High Proteinuria** | zibotentan + dapagliflozin CKD with high proteinuria

H2 2027

- **TROPION-Breast03** | *Datroway + Imfinzi* post-neoadjuvant TNBC
- **TROPION-Breast05** | *Datroway + Imfinzi* 1L PD-L1 CPS ≥10 TNBC
- **CAMBRIA-1** | *Etcamah* adj. switch HR+ HER2- early breast cancer
- **PACIFIC-4** | *Imfinzi* unresect. stg. I/II NSCLC
- **CAPItello-292** | *Truqap* 1L early relapse/ET resistant HR+ adv. BC
- **Bluestar-Endometrial01** | puxi-sam 2-3L B7-H4+ endometrial cancer
- **EvoPAR-Prostate01** | saruparib 1L mCSPC
- **eVOLVE-Cervical** | volrustomig high-risk locally advanced cervical cancer
- **BaxPA** | *Baxfendy* primary aldosteronism
- **JASMINE** | *Saphnelo* idiopathic inflammatory myopathies
- **TILIA** | tozorakimab lower respiratory tract disease

Key upcoming pipeline catalysts are defined by a threshold of non-risk adjusted global peak year revenue expectations as of 10 February 2026. Collaboration partners: Daiichi Sankyo (*Enhertu*, *Datroway*), Hutchmed (*Orpathys*), Ionis (*Wainua*), Amgen (*Tezspire*), Innate Pharma (monalizumab). Appendix: Glossary.

Oncology | BioPharma | Rare

Strategically investing to deliver growth beyond 2030

Significant progress across our transformative technologies in H1 2026

Weight management and CV risk factors	ADCs and radio-conjugates	Next-gen IO bispecifics	Cell therapy & T-cell engagers
First Phase III data for **laroprovstat** H1 2027	First positive Phase III data: **sone-ve** in CLARITY-Gastric01	**16 Phase III** trials across **9 tumour** types	Ongoing Phase III for **AZD0120** in r/r multiple myeloma; further Phase III initiating in newly diagnosed disease
6 Phase III trials initiated for **elecoglipron**	First Phase III data for **puxi-sam** H2 2027 in Bluestar-Endometrial01	**5 Phase III** trials in **combination with ADCs**	Ongoing **surovatamig** Phase IIIs in follicular lymphoma and DLBCL
AZD6234 Phase II readout H1 2026 **AZD6234/AZD9550** Phase IIb expected H2 2026	First patients dosed in **torvu-sam** and **zada-gu** Phase III programmes in Q2 2026	**Subcutaneous rilvegostomig** development ongoing	**AZD0120** and **surovatamig** ongoing early trials in autoimmune disease

Appendix: Glossary.

NMEs with pivotal data readouts before 2030 drive growth into the next decade

>$5bn

- DATROWAY®[1] ✓
- ETCAMAH™ ✓
- AZD0120
- Wholly-Owned ADCs[2]
- saruparib
- BAXFENDY™ ✓
- surovatamig
- elecoglipron | AZD6234 | AZD9550
- rilvegostomig
- laroprovstat franchise
- volrustomig
- tozorakimab ✓

$3-5bn

- sonesitatug vedotin[2] ✓
- balcinrenone + dapagliflozin
- zibotentan + dapagliflozin
- cliramitug
- efzimfotase alfa ✓

Deep late-stage pipeline of multi-blockbuster opportunities

Represents non-risk adjusted peak year revenue, as provided during Investor Day, May 2024 except for tozorakimab and sonesitatug vedotin which were updated at H1 and Q2 2026 results. 1. Peak Year Revenue, non-risk adjusted (Product Sales and Alliance Revenue) across all indications 2. At Investor Day, total wholly-owned ADC portfolio was presented as a >$5bn NRA PYR opportunity. Puxitatug samrotecan and torvutatug samrotecan are wholly-owned ADCs planned to launch by 2030 included now in this bucket. Positive data for sonesitatug vedotin was announced July 2026, which is now presented as a separate $3-$5bn NRA PYR opportunity. Collaboration partners: Daiichi Sankyo (*Datroway*). Appendix: Glossary.

✓ Positive Phase III readout

Oncology | BioPharma | Rare

Increasing confidence in Ambition 2030 and continued growth beyond



Continued commercial momentum in 2026

Strong global demand across medicines

Advancing towards $80bn 2030 Total Revenue ambition[1]

Significant pipeline progress increases confidence

Investment in growth beyond 2030

Strategic focus to fuel growth into next decade

1. 2030 Total Revenue ambition is risk-adjusted and not dependent upon future M&A. Based on Q1 2024 exchange rates.
Appendix: Glossary.



Financial Update

H1 and Q2 2026 – Reported profit and loss

	H1 2026 $m	CER change %	% Total Revenue	Q2 2026 $m	CER change %	% Total Revenue
- Product Sales	*28,896*	*5*	*94*	*14,510*	*4*	*94*
- Alliance Revenue	*1,699*	*29*	*6*	*874*	*33*	*6*
Product Revenue	**30,595**	**6**	**100**	**15,384**	**5**	**100**
- Collaboration Revenue	*77*	*(9)*	*-*	*-*	*n/m*	*-*
Total Revenue	**30,672**	**6**	**100**	**15,384**	**5**	**100**
Gross Margin	*83%*	*-*		*84%*	*-*	
- R&D expense	(7,545)	10	25	(4,053)	13	26
- SG&A expense	(10,571)	10	34	(5,651)	14	37
Total operating expense[1]	(18,402)	10	60	(9,849)	14	64
Other operating income and expense	341	76	1	152	93	1
Operating profit	7,410	2	24	3,164	(13)	21
Tax rate	17%			10%		
Reported EPS	**$3.60**	**3**		**$1.61**	**(2)**	

Due to rounding, the sum of the dollar values and percentages may not agree to totals. Absolute values at actual exchange rates; changes at CER.
1. Total operating expense includes distribution, R&D and SG&A expenses.
Appendix: Glossary.

H1 and Q2 2026 – Core profit and loss

	H1 2026 $m	CER change %	% Total Revenue	Q2 2026 $m	CER change %	% Total Revenue
- Product Sales	*28,896*	*5*	*94*	*14,510*	*4*	*94*
- Alliance Revenue	*1,699*	*29*	*6*	*874*	*33*	*6*
Product Revenue	**30,595**	**6**	**100**	**15,384**	**5**	**100**
- Collaboration Revenue	*77*	*(9)*	*-*	*-*	*n/m*	*-*
Total Revenue	**30,672**	**6**	**100**	**15,384**	**5**	**100**
Gross Margin	*83%*	*+1pp*		*84%*	*+1pp*	
- R&D expense	(7,123)	6	23	(3,662)	5	24
- SG&A expense	(7,909)	6	26	(4,050)	4	26
Total operating expense[1]	(15,318)	6	50	(7,857)	4	51
Other operating income and expense	341	81	1	152	>2x	1
Operating profit	10,510	11	34	5,158	10	34
Tax rate	18%			15%		
Core EPS	**$5.21**	**11**		**$2.63**	**18**	

Due to rounding, the sum of the dollar values and percentages may not agree to totals. Absolute values at actual exchange rates; changes at CER.
1. Total operating expense includes distribution, R&D and SG&A expenses.
Appendix: Glossary.

FY 2026 guidance reiterated

Capital allocation priorities remain unchanged

Net debt/EBITDA 1.3x



FY 2026 Guidance (CER)

Total Revenue	Anticipated to **increase by a mid-to-high single-digit** percentage
Core EPS	Anticipated to **increase by a low double-digit** percentage

- Core tax rate expected to be between 18-22%
- Anticipated FX impact[5]: low single-digit positive impact on Total Revenue and neutral on Core EPS

Due to rounding, the sum of the dollar values and percentages may not agree to totals. 1. Capital expenditure on tangible assets and software-related intangible assets. 2. Comprises purchase and disposal of intangible assets (excluding software-related assets, including AZ Forest), purchase and disposal of non-current asset investments, payments to associates and joint ventures, payments to acquire non-controlling interests, disposal of investments in associates and joint ventures, acquisitions of subsidiaries, net of acquired net debt and payment of contingent consideration on business combinations. The Company mainly uses debt issuance or available cash to finance new Business Development opportunities. 3. Comprises mainly shares purchased by Employee Benefit Trust and recognition of Kendall Square lease liability. 4. Rolling 12-month EBITDA. AstraZeneca credit ratings: Moody's: short-term rating P-1, long-term rating A1, outlook positive. S&P Global Ratings: short-term rating A-1, long-term rating A+, outlook stable. 5. If foreign exchange rates for July 2026 to December 2026 were to remain at the average rates seen in June 2026. Appendix: Glossary.

Net debt position

	30-Jun-26 $m	31-Dec-25 $m
Gross borrowings	(32,239)	(29,622)
Cash & cash equivalents	4,893	5,711
Other investments	75	30
Net derivative financial instruments	359	507
Closing net debt [1]	**(26,912)**	**(23,374)**

1. Net debt is a non-GAAP measure. The equivalent GAAP measure to Net debt is 'liabilities arising from financing activities', which excludes the amounts for cash and overdrafts, other investments and non-financing derivatives shown above. Further details are available in our Q2 results announcement published on 27 July 2026.

Liquidity, debt and rating summary

- Strong liquidity at 30 June 2026:
  - Group cash and investments of $5.0bn
  - Undrawn $4.9bn committed bank facilities available until April 2031

- Access to diverse sources of funding through US and European term debt and commercial paper programmes

Programme	Last Updated	Valid to	Limit	Rating (Moody's / S&P)	Utilisation as at 30 June 2026 [1]
SEC Shelf Registration Statement	Mar-24	Mar-27	Unlimited	A1 / A+	USD 21.0bn
Euro Medium Term Note Programme	Jun-26	Jun-27	Unlimited	A1 / A+	USD 5.6bn
US Commercial Paper	N/A	N/A	USD 15bn	A-1 / P-1	USD 2.4bn
Euro-Commercial Paper	May-20	N/A	EUR 10bn	Issuer rating	None

[1] Notional bond values. FX converted at 30 June 2026 spot rates (USD/EUR 0.876; USD/GBP 0.755)

- The Board continues to target a strong, investment-grade credit rating

- The Company is currently rated as:
  - Moody's: A1 Positive outlook / P-1
  - Standard & Poor's: A+ Stable outlook / A-1

Smooth debt maturity profile

Debt Maturity Profile at 30 June 2026 [1]



1. Notional bond values. FX converted at 30 June 2026 spot rates (USD/EUR 0.876; USD/GBP 0.755). Current portion of leases of $426m are included in 2026, while non-current leases of $2,322m have been excluded from the chart.

Appendix

AstraZeneca P&L reference table

P&L line-item definitions

	P&L line-item definition
Product Sales	• Recognises sales from territories where Group has lead commercialisation • Recognises supply of *Beyfortus* to Sanofi
Alliance Revenue	• Alliance Revenue comprises income arising from the ongoing operation of collaborative arrangements related to sales made by collaboration partners, where AstraZeneca is entitled to a share of gross profits, share of revenues or royalties, which are recurring in nature while the collaboration agreement remains in place[1]
Product Revenue	• The sum of Product Sales and Alliance Revenue
Collaboration Revenue	• Recognises any development or sales-based milestone received on partnered medicines as well as any upfront payments associated with business development where AstraZeneca retains a significant ongoing economic interest in the product
Total Revenue	• Sum of Product Sales, Alliance Revenue and Collaboration Revenue
Gross Margin	• Calculated by dividing Gross Profit by Total Revenue
Other operating income & expense	• Other operating income and expense is generated from activities outside of the Group's normal course of business, which includes Other income from divestments of or full out-license of assets and businesses including royalties and milestones where the Group does not retain a significant continued interest
Core[2] Operating margin	• Defined as Core Operating profit as a percentage of Total Revenue

1. Partnered medicines include: *Enhertu*, *Lynparza, Datroway*, *Beyfortus*, *Tezspire*, *Wainua*. 2. Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges.
Appendix: Glossary.

AstraZeneca P&L

2026 P&L modelling considerations

P&L line	P&L
Total Revenue	• Expected to grow by a mid-to-high single digit percentage at CER (guidance)
Gross margin	• Core gross margin expected to be stable to slightly better vs. 2025
R&D	• Core R&D expenses expected to be at the upper end of the low 20%s range (of Total Revenue)
Other operating income	• Similar level of OOI anticipated in 2H as in 1H 2026
Finance expenses	• Core Finance expenses anticipated to be higher vs. 2025
Tax	• Core tax rate expected to be between 18-22% for the full year
Core EPS	• Expected to grow by a low double-digit percentage at CER (guidance)
FX-impact	• If foreign exchange rates for July 2026 to December 2026 were to remain at the average rates seen in June 2026, a low single-digit positive impact is anticipated on Total Revenue and a neutral impact on Core EPS

Appendix: Glossary.

AstraZeneca in non-small cell lung cancer



All numbers are approximate. Illustrative settings and populations, not to scale. Lung Cancer map reflects Phase III/pivotal trials.
Collaboration partners: Daiichi Sankyo (*Enhertu*, *Datroway*), Hutchmed (*Orpathys*).
Appendix: Glossary.

AstraZeneca in breast cancer



All numbers are approximate. Illustrative settings and populations, not to scale. Breast Cancer map reflects Phase III/pivotal trials.
Collaboration partners: Daiichi Sankyo (*Enhertu*, *Datroway*), Merck & Co., Inc. (*Lynparza*).
Appendix: Glossary.

AstraZeneca in gastric cancer



All numbers are approximate. Illustrative settings and populations, not to scale. Gastric cancer map reflects ongoing active Phase III/pivotal trials.
Collaboration partner: Daiichi Sankyo (*Enhertu*).
Appendix: Glossary.

AstraZeneca in bladder cancer

High-risk NMIBC	MIBC	1L mUC
96k	68k	46k
Imfinzi + BCG induction and maintenance **POTOMAC**	Neoadjuvant *Imfinzi* + CTx → adjuvant *Imfinzi* **NIAGARA** cis-eligible ~50%	*Imfinzi* + CTx ± *Imjudo* **NILE**
	Neoadjuvant *Imfinzi* + enfortumab vedotin ± *Imjudo* → adjuvant *Imfinzi* ± *Imjudo* **VOLGA** cis-ineligible/ refusal ~50%	

Key: DXd ADC | IO | AZ ADC | IO bispecific | launched and established SoC | launched indication

All numbers are approximate. Illustrative settings and populations, not to scale.
Appendix: Glossary.

Q2 2026 Reconciliation of Reported to Core Financial Measures

	Reported $m	Restructuring $m	Intangible Asset Amortisation & Impairments $m	Other[1] $m	Core[2] $m
Gross Profit	12,861	(8)	8	2	12,863
Distribution Expense	(145)	-	-	-	(145)
R&D Expense	(4,053)	36	355	-	(3,662)
SG&A Expense	(5,651)	72	1,183	346	(4,050)
Other Operating Income & Expense	152	-	-	-	152
Operating Profit	3,164	100	1,546	348	5,158
Net Finance Expense	(355)	-	-	15	(340)
Taxation	(291)	(27)	(324)	(89)	(731)
Earnings Per Share	$1.61	$0.05	$0.79	$0.18	$2.63

1. Further details are available in our Q2 2026 results announcement published on 27 July 2026.
2. Each of the measures in the Core column in the above table are non-GAAP financial measures.

H1 2026 Reconciliation of Reported to Core Financial Measures

	Reported $m	Restructuring $m	Intangible Asset Amortisation & Impairments $m	Other[1] $m	Core[2] $m
Gross Profit	25,471	(3)	16	3	25,487
Distribution Expense	(286)	-	-	-	(286)
R&D Expense	(7,545)	57	364	1	(7,123)
SG&A Expense	(10,571)	106	2,156	400	(7,909)
Other Operating Income & Expense	341	-	-	-	341
Operating Profit	7,410	160	2,536	404	10,510
Net Finance Expense	(675)	-	-	54	(621)
Taxation	(1,124)	(40)	(514)	(111)	(1,789)
Earnings Per Share	$3.60	$0.08	$1.31	$0.22	$5.21

1. Further details are available in our Q2 2026 results announcement published on 27 July 2026.
2. Each of the measures in the Core column in the above table are non-GAAP financial measures.

Prudent treasury risk-management policies

The Company operates with a centralised Treasury structure so that key Treasury risks are managed at a Group level.

Liquidity Policy
- Prudent level of available cash and unutilised credit facilities
- Group funding centrally managed

Investment policy
- Security and liquidity
- Financial counterparty limits

Foreign Exchange Policy
- Foreign Exchange exposures managed centrally
- Transactional currency exposures substantially hedged

Interest Rate Policy
- Aim to broadly match level of floating rate debt to cash over time
- Significant portion of financial liabilities at fixed interest rates

Credit Risk
- Cash managed centrally
- Derivatives positions predominately cash collateralised

Glossary

1L, 2L, 3L	first-, second-, third-line
ADA	American Diabetes Association
ADC	antibody-drug conjugate
adv.	advanced
AI	aromatase inhibitor
AKT1	AKT serine/threonine kinase 1
AKTi	AKT inhibitor
ATTR-CM	transthyretin amyloid cardiomyopathy
ATTR-PN	transthyretin amyloid polyneuropathy
AZ	AstraZeneca
BCG	Bacillus Calmette-Guérin
BTKi	Bruton's tyrosine kinase
C5	complement component 5
CapEx	capital expenditure
CDK4/6i	cyclin-dependent kinase 4/6 inhibitor
CER	constant exchange rates
CFO	net cash inflow from operating activities
CHMP	Committee for Medicinal Products for Human Use
CKD	chronic kidney disease
CLDN18.2	Claudin-18.2
CLL	chronic lymphocytic leukaemia
CN	China
COPD	chronic obstructive pulmonary disease
CPS	combined positive score
CR	Collaboration Revenue
CRT	chemoradiotherapy
CSA-AKI	cardiac surgery-associated acute kidney injury
CTx	chemotherapy
CV	cardiovascular
CVRM	Cardiovascular, Renal and Metabolism
DLBCL	Diffuse Large B-Cell Lymphoma
Dxd	deruxtecan
EBITDA	Reported Profit before tax after adding back net finance expense, results from joint ventures and associates, and charges for depreciation, amortisation and impairment
EFS	event-free survival
EGFRm	epidermal growth factor receptor-mutant
EGPA	eosinophilic granulomatosis with polyangiitis
EM	Emerging Markets
epi	epidemiology
EPS	earnings per share
ERoW	Established Rest of World
ERS	European Respiratory Society
ESC	European Society of Cardiology
ESR1m	estrogen receptor alpha-mutated
EU	Europe
EV	enfortumab vedotin
FDC	fixed-dose combination
FLOT	fluorouracil, leucovorin, oxaliplatin and docetaxel
FP	fluoropyrimidine
FSI	first subject in
FX	foreign exchange
FY	Fiscal Year
G7	US, Japan, EU5
gBRCAm	germline BRCA-mutated breast cancer
GI	gastrointestinal
GLP-1	glucagon-like peptide-1
gMG	generalised myasthenia gravis
GU	genitourinary
HbA1c	hemoglobin A1c
HCC	hepatocellular carcinoma
HER2-/negative	human epidermal growth factor receptor 2-negative
HER2-low	human epidermal growth factor receptor 2-low
HER2-ultralow	human epidermal growth factor receptor 2-ultralow
HER2+/positive	human epidermal growth factor receptor 2-positive
HER2m	human epidermal growth factor receptor 2-mutant
HF	heart failure
HFpEF	heart failure with preserved ejection fraction
HPP	hypophosphatasia
HR+/positive	hormone receptor-positive
HSCT-TMA	hematopoietic stem cell transplantation-associated thrombotic microangiopathy
i.v.	intravenous
ID	Infectious Diseases
IgAN	immunoglobulin A nephropathy
IL-5	interleukin-5
IO	immuno-oncology
ISR	injection site reaction
JP	Japan
LOE	loss of exclusivity
M&A	mergers and acquisitions
mCSPC	metastatic castration-sensitive prostate cancer
MIBC	muscle invasive bladder cancer
mUC	metastatic urothelial carcinoma
ngSERD	next-generation selective estrogen receptor degrader
NME	new molecular entity
NMIBC	non-muscle invasive bladder cancer
NMR+	normalised membrane ratio positive
NSCLC	non-small cell lung cancer
NSQ	non-squamous
NST	neoadjuvant systemic therapy
OS	overall survival
PALB2m	partner and localizer of BRCA2
PARPi	poly-ADP ribose polymerase inhibitor
PD-L1	programmed cell death ligand 1
PFS	progression free survival
PIK3CA	phosphatidylinositol 3-kinase catalytic subunit alpha
P&L	profit and loss
PNH	paroxysmal nocturnal haemoglobinuria
pp	percentage point
PR	Product Revenue
PS	Product Sales
PTEN	phosphatase and TENsin homolog deleted on chromosome 10
PYR	Peak-Year Revenue
QoL	quality of life
RA	receptor agonist
r/r	refractory / recurrent
R&D	Research & Development
R&I	Respiratory & Immunology
SBRT	stereotactic body radiotherapy
SC	subcutaneous
SERD	selective estrogen receptor degraders
SG&A	Selling, General & Administrative
SoC	standard-of-care
SQ	squamous
Stg.	stage
T2D	type 2 diabetes
tBRCAm	tumor BRCA mutation
THP	docetaxel, trastuzumab and pertuzumab
TKI	tyrosine kinase inhibitor
TL07	TROPION-Lung07
TL08	TROPION-Lung08
TNBC	triple negative breast cancer
TROP2	trophoblast cell surface antigen 2
TSLP	thymic stromal lymphopoietin
US	United States
VBP	volume-based procurement

AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK
+44(0)203 749 5000
www.astrazeneca.com